Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sequoia Fund wins...

    Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

    Written by supriya kashyap kashyap Published On 2017-02-26T10:42:19+05:30  |  Updated On 26 Feb 2017 10:42 AM IST
    Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

    New York : A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc (VRX.TO), causing billions of dollars of losses.


    Justice O. Peter Sherwood of the State Supreme Court in White Plains, New York, said Sequoia shareholders failed to show it would have been futile, prior to suing in January 2016, to demand that the mutual fund's directors step in to unwind the investment because of their alleged conflicts of interest.


    The judge said the shareholders could try to amend their complaint, but that this appeared to be "a fool's errand."


    Sherwood issued his ruling during a Feb. 15 hearing. A transcript was made public eight days later.


    Sequoia shareholders had sued Sequoia's investment adviser Ruane, Cunniff & Goldfarb; portfolio managers Robert Goldfarb and David Poppe; and three directors including author and chairman Roger Lowenstein.


    The defendants were accused of gross negligence for letting Sequoia plow nearly one-third of its assets into Valeant, despite a policy capping its stake at 25 percent.


    Lawyers for the shareholders did not immediately respond to requests for comment on Friday.


    Valeant shares have tumbled 93 percent in the last 1-1/2 years amid criticism of the Canadian drug company's pricing and business practices, and regulatory and congressional probes.


    Goldfarb, who co-managed Sequoia for 36 years, retired as Ruane, Cunniff's chief executive last March.


    Sequoia sold its last Valeant shares in June, but its losses have left it still trailing 98 percent of its peers over five years, while assets have shrunk by more than half to $4.2 billion, Morningstar said on Friday.


    Amy Roy, a lawyer at Ropes & Gray, which represents Sequoia, said its independent directors were gratified that Sherwood "recognized the central oversight role of mutual fund boards."


    Poppe, who remains at Sequoia, told shareholders last July that the fund had experienced "interesting times," and that "our goal is to be much less interesting" in the future.


    Ruane, Cunniff's late founder, William Ruane, was a friend and classmate of Buffett. When Buffett shut his investment partnership in 1969 to focus on Berkshire Hathaway Inc (BRKa.N), he recommended that clients invest with Ruane.


    Sequoia's largest current investment is Berkshire. Buffett last April called Valeant's business model "enormously flawed," and Berkshire Vice Chairman Charlie Munger last week called Valeant's story "too good to be true."


    The case is Epstein et al v. Ruane, Cunniff & Goldfarb Inc et al, New York State Supreme Court, New York County, No. 650100/2016.

    Amy RoyBerkshire HathawayRoger LowensteinSequoia FundValeantWarren Buffett
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok